A delivery assembly includes a console including a vial containment region and a vial engagement mechanism extending from the console within the vial containment region. The engagement mechanism is configured to engage a vial assembly. The delivery assembly further includes a sled assembly removably coupled to the console at the vial containment region and a safety shield removably coupled to the console over the vial containment region such that the vial engagement mechanism and the sled assembly are encapsulated within the safety shield when the safety shield is coupled thereto. The sled assembly, the vial assembly, and the safety shield are configured to inhibit radioactive emissions from within the vial containment region.

A delivery device for intravenous delivery of microparticles to a patient. The delivery device is fluidly connectable to (i) a first source of an injection medium and (ii) a second source of an injection medium. The delivery device includes: a first fluid inlet fluidly connectable to the first source of the injection medium, a fluid outlet, a fluid mixer fluidly connecting the first fluid inlet to the fluid outlet, a second fluid inlet fluidly connectable to the second source of the injection medium, and a source of microparticles fluidly connecting the second fluid inlet to the fluid mixer. When fluid flows from the second source of the injection medium into the delivery device: the second injection medium fluidly drives microparticles from the source of microparticles into the fluid mixer, and the fluid outlet dispenses to the patient an injection medium that includes the microparticles.

A rotating shield brachytherapy (RSBT) apparatus includes a radiation source, at least one applicator, a catheter, a catheter drive assembly, a robotic positioning system, and a connection system. The applicator(s) is configured to be inserted or implanted into a patient. A distal end portion of the catheter has at least one radiation shield and is configured to receive a wire-mounted radiation source. The catheter drive assembly causes helical motion of the catheter and engages the proximal end portion of the catheter to selectively rotate the catheter about a longitudinal axis. The robotic positioning system aligns the catheter drive assembly, in both position and angular orientation at a modifiable rate, with the applicator(s), or to any programmed point in space. The connection system couples the catheter drive assembly to the applicator(s), and further decouple the catheter drive from the applicator(s). When the applicator(s) is coupled to the catheter drive assembly, the catheter can be advanced into, and out of, the at least one applicator at a variable rate through operation of the catheter drive a

A multi-purpose balloon catheter includes a catheter having a proximal end portion, a central portion and a non-branching distal end portion, a plurality of lumens associated with the catheter extending from the proximal end portion, and a plurality of inflatable balloons positioned in the central portion and/or the non-branching distal end portion. Each of the plurality of inflatable balloons is communicatively associated with a corresponding one of the plurality of lumens, the plurality of inflatable balloons being selectively inflated or deflated to position and stabilize the catheter in a cavity for delivery of a medical treatment. The catheter can include an extraction point associated with a lumen to remove fluids and materials from the cavity, and a connector associated with a corresponding lumen adapted to selectively receive one or more of a fluid medium or a radioactive isotope provided to a corresponding lumen for delivery of the medical treatment.

A glass material that includes: from about 0.55 to about 0.85 mole fraction of SiO.sub.2; from about 0.01 to about 0.23 mole fraction of Na.sub.2O, K.sub.2O, or a combination of Na.sub.2O and K.sub.2O; from about 0.05 to about 0.28 mole fraction of: Y.sub.2O.sub.3, BaO, or a combination of Y.sub.2O.sub.3 and BaO; and optionally Ta.sub.2O.sub.5. In the glass material, the sum of the Y.sub.2O.sub.3, the BaO and the optional Ta.sub.2O.sub.5 is from about 0.10 to about 0.31 mole fraction. The glass material may be in the form of microspheres. The microspheres may be used for vascular embolization and/or radiologic imaging.

A method of treatment including: selecting tissue to be exposed to radiation for gradual closure of one or more blood vessel within the tissue to be exposed radiation; selecting radiation levels to promote gradual constriction of the one or more vessel; exposing the tissue to be exposed radiation to selected radiation levels.

Embodiments of the disclosure may be drawn to brachytherapy applicators. Exemplary applicators may include an interstitial tube having a body with a proximal end and a distal end and a central conduit extending from the distal end of the body, wherein the central conduit includes a proximal opening, a distal opening, and a channel extending from the proximal opening to the distal opening, and wherein the proximal opening is offset from an axis of the body. The proximal opening may be configured to fluidly connect to a brachytherapy guide tube, and the channel of the central conduit may be dimensioned to receive at least one of a needle or a catheter therethrough.

A vial assembly includes a vial and a needle with at least one port. The vial includes a particulate material, a septum, a neck region including a first width, and a particulate region including a second width greater than the first width. The vial assembly is configured to move to a locked position. The needle may be configured to puncture the septum with the at least one port configured to be in the neck region when in the locked position. The at least one port may be configured to inject a fluid into the vial assembly to mix with the particulate material upon actuation of a vial engagement mechanism in a first direction and to receive a resulting mixed fluid from the vial assembly upon actuation of the vial engagement mechanism in a second direction opposite the first direction.

Disclosed herein is a therapeutically active agent usable in the treatment of pulmonary arterial hypertension (PAH), for use in the treatment of pulmonary arterial hypertension, as well as methods of treating PAH, said treatment and methods comprising administering such an active agent and effecting pulmonary artery denervation in the subject. In some aspects, a sub-therapeutically effective amount of the active agent is administered. In some aspects, the method is devoid of administering such an active agent for at least one month subsequent to the denervation. Further disclosed is a method of treating PAH comprising determining a responsiveness of the subject to at least one therapeutically active agent usable in treating PAH; and effecting pulmonary artery denervation in a subject responsive to the active agent(s).

Disclosed herein are methods of treating a patient in need of therapy for prostate cancer comprising delivering a β-radiation-emitting composition into the prostatic vasculature. In some embodiments, an absorbed dose of 60 Gy to 200 Gy is delivered to the prostate. In some embodiments, the β-radiation-emitting composition is delivered into the arterial vasculature of the prostate via a catheter. In some embodiments, the β-radiation-emitting composition comprises a suspension of the β-radiation-emitting particles in an aqueous liquid.